AzTrials
AzTrials

HIV PreventionNCT05968755

Leveraging Chatbot to Improve PrEP in the Southern United States

A study testing A chatbot designed to promote PrEP awareness and uptake for Black MSM and General educational messages in people with HIV Prevention and PrEP Awareness, run by Yale University at 4 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this study is to develop a chatbot intervention to promote PrEP awareness and uptake among Black men who have sex with men (MSM) in the Southern United States. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
HIV Prevention, PrEP Awareness, PrEP Uptake
What is being tested?
A chatbot designed to promote PrEP awareness and uptake for Black MSM and General educational messages
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
145 participants
Where
4 sitesUnited States
Study dates
13 Jul 2026to 1 Jul 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Being cisgender Black male
  • Being aged ≥ 18 years
  • Having Internet access
  • Speaking English
  • Self-reporting condomless sex with another man in the past 6 months
  • Living in the U.S. South
  • HIV negative or untested.

Who cannot join

  • Not residing in a U.S. Census Bureau-defined Southern state: AL, AR, DE, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV.
  • Having received antiretroviral therapy (ART) treatment.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States4 sites, 4 recruiting
  • NAESM, Inc

    Atlanta, Georgia, 30318

    Research Coordinator, 404-691-8880, ak@naesminc.org

    Recruiting
  • RAO Community Health

    Charlotte, North Carolina, 28202

    Director of Programs, 704-237-8793, zharris@raoassist.org

    Recruiting
  • Care 4 U Community Health Center

    Miami, Florida, 33127

    Chief Operating Officer, 305-835-0101, aichite@care4uchc.org

    Recruiting
  • Community Care Resources of FL (CCRSFL)

    Pembroke Pines, Florida, 33027

    Executive Director, 877-287-2520, victoria@ccrsfl.com

    Recruiting

Other trials in United States

About this study

Official title: Leveraging Chatbot Technology to Improve PrEP Awareness and Uptake Among Black MSM in the Southern United States

The purpose of this study is to develop a chatbot intervention to promote PrEP awareness and uptake among Black men who have sex with men (MSM) in the Southern United States.

Read the detailed description

In the United States (US), the epicenter of the HIV epidemic is in the South. The HIV-related death rate in the US South is high, but engagement with quality HIV prevention services and care is low. Although only 38% of the US population lives in the South, the region accounts for 51% of new HIV infections. Gay, bisexual, and other men who have sex with men (MSM) account for 60% of new infections among African Americans in the South. Black MSM are one of the most vulnerable groups to HIV transmission in the US. HIV testing and PrEP uptake in Black MSM, however, remain low (10%) due to multiple factors including stigma, sexual-orientation based discrimination and low PrEP awareness among Black MSM. Innovative strategies that motivate and provide guidance for PrEP among Black MSM in the US South are therefore urgently needed. Chatbot technology should be tested and implemented to help improve PrEP awareness and uptake in the US South. In this project, the investigators aim to develop and pilot test to assess the acceptability and feasibility of a chatbot for PrEP awareness and uptake relative to treatment as usual (control).

Being tested
A chatbot designed to promote PrEP awareness and uptake for Black MSM, General educational messages

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • A chatbot designed to promote PrEP awareness and uptake for Black MSMDevice

    Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.

  • General educational messagesOther

    Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.

Study groups in NCT05968755
Study groupRoleWhat they receive
Intervention groupExperimentalNot described
Receives: Device: A chatbot designed to promote PrEP awareness and uptake for Black MSM
Control groupPlacebo comparatorNot described
Receives: Other: General educational messages

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline PrEP awareness in 90 days

    PrEP awareness will be measured as the proportion of participants who are aware of PrEP. Specifically, the investigators will collect PrEP awareness by asking participants standardized questions through a Qualtrics survey.

    Measured: At the baseline, 30, 60, and 90 days

  2. Change from baseline PrEP uptake in 90 days

    PrEP uptake will be measured as the mean of the frequency of taking PrEP medication. Specifically, the investigators will collect PrEP uptake by asking participants through a Qualtrics survey if they have been taken PrEP at baseline and every 30 days. If participants respond that they have taken PrEP, the investigators will ask them the date and frequency of taking it and ask them to upload a photo of their PrEP for verification to reduce social desirability bias in responses.

    Measured: At the baseline, 30, 60, and 90 days

Secondary outcomes (6)
  1. Usability score

    The usability score will be measured by the System Usability Scale, which is 5-point Likert scale consisted of 10 questions. Participants' scores range from 0 to 100. A score of 68 is average, below 68 is poor, above 68 is good, and above 80.3 is excellent.

    Measured: At 90 days

  2. Recommendation score

    The recommendation score will be calculated by a Net Promote Score, which measures MSM's likelihood to recommend the chatbot to other MSM friends. The score ranges from 0 to 10. The higher the score, the better the recommendation score.

    Measured: At 90 days

  3. Acceptability score

    Acceptability, defined as the extent to which the chatbot is suitable and satisfactory to MSM, will be measured using the standardized Customer Satisfaction Scale "How would you rate your overall satisfaction with the chatbot?" and a 5-point Likert question "How would you rate the likelihood of continuing to use the chatbot?"

    Measured: At 90 days

  4. Practicality score

    Practicality defined as the extent to which the chatbot provides real-time Self-Determination theory inputs, will be measured using a 5-point Likert question "How would you rate the overall quality of the chatbot?"

    Measured: At 90 days

  5. Demand score

    Demand, defined as the level of integration to which the chatbot fits into the MSM-preferred online platform, will be measured by the number of actual use documented on developer's platform.

    Measured: At 90 days

  6. Adaptation score

    Adaptation, defined as the extent to which the chatbot can be integrated into other social-networking apps, will be measured by asking "How likely would you use the chatbot if embedded on other apps?"

    Measured: At 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2023
  2. Study start13 Jul 2026
  3. Primary completion31 Mar 2027 (estimated)
  4. Study completion1 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
145 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05968755
Sponsor's protocol ID
2000035242
Other IDs
000
Status last verified
Sep 2026
First submitted
22 May 2023
Last updated
23 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Centers for Disease Control and Prevention. HIV and African American Gay and Bisexual Men. [cited 2022 August 4]; Available from: https://www.cdc.gov/hiv/group/msm/bmsm.html.

  • Adeagbo O, Harrison S, Qiao S, Li X. Pre-Exposure Prophylaxis (PrEP) Uptake among Black Men Who Have Sex with Men (BMSM) in the Southern U.S. Int J Environ Res Public Health. 2021 Sep 15;18(18):9715. doi: 10.3390/ijerph18189715.

    PubMed 34574652
  • Watson RJ, Eaton LA, Maksut JL, Rucinski KB, Earnshaw VA. Links Between Sexual Orientation and Disclosure Among Black MSM: Sexual Orientation and Disclosure Matter for PrEP Awareness. AIDS Behav. 2020 Jan;24(1):39-44. doi: 10.1007/s10461-019-02696-1.

    PubMed 31606770

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in